Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2002-09-16
2008-10-28
Allen, Marianne P (Department: 1647)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007200, C530S350000
Reexamination Certificate
active
07442512
ABSTRACT:
The present invention provides methods for identifying an agent that specifically binds and/or modulates one topology of chemokine receptor but not a second topology of the receptor. Such agents are useful as therapeutics for diseases or conditions associated with a particular chemokine receptor topology. Moreover, the agents are useful for detecting a particular topology of a chemokine receptor, thereby diagnosing disease or predisposition for a disease. In addition, the agents are useful for identifying and isolating cells that express a particular topology of a chemokine receptor.
REFERENCES:
patent: 4166452 (1979-09-01), Generales, Jr.
patent: 4256108 (1981-03-01), Theeuwes
patent: 4265874 (1981-05-01), Bonsen et al.
patent: 4927838 (1990-05-01), Guthrie et al.
patent: 5994519 (1999-11-01), Osbourn et al.
patent: 6084075 (2000-07-01), Lind et al.
patent: 6140064 (2000-10-01), Loetscher et al.
patent: 6156520 (2000-12-01), Inglese et al.
patent: 6180336 (2001-01-01), Osbourn et al.
patent: 6184358 (2001-02-01), Loetscher et al.
patent: 6329159 (2001-12-01), Andrew et al.
patent: 6365356 (2002-04-01), Gershengorn
patent: 6448054 (2002-09-01), Poznansky et al.
patent: 6537764 (2003-03-01), Gerard et al.
patent: 2002/0004215 (2002-01-01), Osbourn et al.
patent: 2002/0025536 (2002-02-01), Gyuris et al.
patent: 2002/0034757 (2002-03-01), Cubicciotti
patent: 2002/0037539 (2002-03-01), Qin et al.
patent: 2002/0048786 (2002-04-01), Rosen et al.
patent: 2002/0061599 (2002-05-01), Elling et al.
patent: 2002/0061834 (2002-05-01), Rosen et al.
patent: 2002/0064770 (2002-05-01), Nestor, Jr. et al.
patent: 2002/0076710 (2002-06-01), Papsidero et al.
patent: 0 897 980 (1999-02-01), None
patent: WO 98/11218 (1998-03-01), None
patent: WO 98/14480 (1998-04-01), None
patent: WO 99/50461 (1999-10-01), None
Trentin et al. The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. Journal of Clinical Investigation vol. 104/1(Jul. 1999).
McKnight et al. Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent. Journal of Virology vol. 71, No. 2 (Feb. 1997).
Fantuuzzi et al., Loss of CCR2 expression and functional response to monocyte chemotactic protein (MCP-1) during differentiation of human monocytes:role of secreted MCP-1 in the regulation of the chemotactic response. Blood, vol. 94/3 pp. 875-883 (Aug. 1, 1999).
Hill et al. The amino terminus of human CCR5 is required for its function as a receptor for diverse human and simian immunodeficiency virus envelope glycoproteins. Virology 248, pp. 357-371 (1998).
Schecter et al. Human vascular smooth muscle cells possess functional CCR5. The Journal of Biological Chemistry, vol. 275, No. 8, pp. 5466-5471 (Feb. 2000).
Mohle et al. Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor (SDF-1). Leukemia vol. 13, pp. 1954-1959 (1999).
Baribaud et al. The impact of chemokine receptor conformational heterogeneity on HIV infection. Cellular and Molecular Biology 47(4):653-660 (Jun. 2001).
Babcock, G. J. et al. “Ligand Binding Characteristics of CXCR4 Incorporated into Paramagnetic Proteoliposomes,”J. Biol. Chem.2001, pp. 38433-38440, vol. 276, No. 42.
Baribaud, F. et al. “Antigenically Distinct Conformations of CXCR4,”J. of Virol.2001, pp. 8957-8967, vol. 75, No. 19.
Dairaghi, D. J. “HHV8-Encoded vMIP-I Selectively Engages Chemokine Receptor CCR8,”J. Biol. Chem.1999, pp. 21569-21574, vol. 274, No. 31.
Dragic, T. “An Overview of the Determinants of CCR5 and CXCR4 co-Receptor Function,”J. Gen. Virol.2001, pp. 1807-1814, vol. 82.
Förster, R. et al. “Intracellular and Surface Expression of the HIV-1 Coreceptor CXCR4/Fusin on Various Leukocyte Subsets: Rapid Internalization and Recycling Upon Activation,”J. Immunol.1998, pp. 1522-1531, vol. 160.
Gerlach, L. O. et al. “Molecular Interactions of Cyclam and Bicyclam Non-Peptide Antagonists with the CXCR4 Chemokine Receptor,”J. Biol. Chem.2001, pp. 14153-14160, vol. 276, No. 17.
Gosling, J. et al. “Cutting Edge: Identification of a Novel Chemokine Receptor That Binds Dendritic Cell-and T Cell-Active Chemokines Including ELC, SLC, and TECK,”J. Immunol.2000, pp. 2851-2856, vol. 164.
Kledal, T. N. et al. “A Broad-Spectrum Chemokine Antagonist Encoded by Kaposi's Sarcoma-Associated Herpesvirus,”Science277, pp. 1656-1659, vol. 277.
Lee, B. et al. “Epitope Mapping of CCR5 Reveals Multiple Conformational States and Distinct but Overlapping Structures Involved in Chemokine and Coreceptor Function,”J. Biol. Chem.1999, pp. 9617-9626, vol. 274, No. 14.
Müller, A. et al. “Involvement of Chemokine Receptors in Breast Cancer Metastasis,”Nature2001, pp. 50-56, vol. 410.
Parolin, C. et al. “Use of Murine CXCR-4 as a Second Receptor by Some T-Cell-Tropic Human Immunodeficiency Viruses,”J. Virol.1998, pp. 1652-1656, vol. 72, No. 2.
Wegner, S. A. et al. “Genomic Organization and Functional Characterization of the Chemokine Receptor CXCR4, a Major Entry Co-Receptor for Human Immunodeficiency Virus Type 1,”J. Biol. Chem.1998, pp. 4754-4760, vol. 273, No. 8.
Yoshida, T. et al. “Identification of Single C Motif-1/Lymphotactin Receptor XCR1,”J. Biol. Chem.1998, pp. 16551-16554, vol. 273, No. 26.
Moepps, et al. “Two murine homologues of the human chemokine receiptor CXCR4 mediating stromal cell-derived factor 1α activation of G12are differentially expressed in vivo”,Eur. J. Immunol., 1997 27:2102-2112.
Ebert, Lisa M. et al.; “Coregulation of CXC Chemokine Receptor and CD4 Expression on T Lymphocytes During Allogeneic Activation”; 2001,Journal of Immunology, vol. 166, No. 8, pp. 4870-4878.
Abdel-Magid, Ahmed F. et al.; “Reductive Amination of Aldehydes and Ketones by Using Sodium Triacetoxyborohydride”;Tetrahedron Lett., 1990, vol. 31, pp. 5595-5598.
Barney, Charlotte L. et al.; “A Convenient Synthesis of Hindered Amines and α-Trifluoromethylamines from Ketones”;Tetrahedron Lett., 1990, vol. 31, pp. 5547-5550.
Bertolini, Francesco et al.; “Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma”;Blood, 2000, vol. 96, No. 1, pp. 282-287.
Bertolini, Francesco et al.; “CXCR4 Neutralization, a Novel Therapeutic Approach for Non-Hodgkin's Lymphoma”;Cancer Research, 2002, vol. 62, pp. 3106-3112.
Gribble, Gordon, W. et al.; “Reactions of Sodium Borohydride in Acidic Media; XVI. N-Methylation of Amines with Paraformaldehyde/Trifluoroacetic Acid”;Synthesis, 1987, pp. 709-711.
Kevill, Dennis N. et al.; “Correlation of the Rates of Solvolysis of Allyl and Benzyl Arenesulphonates”;Journal of Chemical Society Perkin Trans., 1984, vol. 2, pp. 717-720.
Lin, Engnian et al.; “Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2”;Proc. Natl. Acad. Sci.1998, vol. 95, pp. 8829-8834.
Liotta, Lance A.; “An attractive force in metastasis”;Nature, 2001, vol. 410, pp. 24-25.
Mattson, Ronald J. et al.; “An Improved Method for Reductive Alkylation of Amines Using Titanium (IV) Isopropoxide and Sodium Cyanoborohydride”;J. Org. Chem., 1990, vol. 55, pp. 2552-2554.
Muller, Anja et al.; “Involvement of chemokine receptors in breast cancer metastasis”;Nature, 2001, vol. 410, pp. 50-56.
Neises, Bernhard et al.; “Simple Method for the Esterification of Carboxylic Acids”;Angew. Chem. Int. Ed. Engl., 1978, vol. 17, No. 7, pp. 522-524.
Neote, Kuldeep, et al.; “Molecular Cloning, Functional Expression, and Signaling Characteristics of a C-C Chemokine Receptor”;Cell, 1993, vol. 72, pp. 415-425.
Oppenheim, Joost
Burns Jennifer M.
Howard Maureen C.
Miao Zhenhua
Premack Brett A.
Schall Thomas J.
Allen Marianne P
ChemoCentryx, Inc.
DeBerry Regina M
Townsend and Townsend / and Crew LLP
LandOfFree
Compositions and methods for detecting and treating diseases... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for detecting and treating diseases..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for detecting and treating diseases... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3987952